ReviewFrontiers in cellular and infection microbiology2012
Escherichia coli O157:H7-Clinical aspects and novel treatment approaches.
Review in Frontiers in cellular and infection microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Molecular characterization of multi-drug resistance Escherichia coli O157:H7 from calf feces and cow milk in Bangladesh.Scientific reports · 2026Article
- Efficacy of chemical sanitizers againstFrontiers in microbiology · 2026Article
- Phage Encapsulation and Delivery Technology: A Strategy for Treating Drug-Resistant Pathogenic Microorganisms.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Synthesis of Novel Bioactive Lipophilic Hydroxyalkyl Esters and Diesters Based on Hydroxyphenylacetic Acids.Molecules (Basel, Switzerland) · 2025Article
- A Paradigm Shift in SSTI Management: The Multifunctional Role of Extracellular Vesicles.International journal of molecular sciences · 2025Review
- Phylogroup Homeostasis ofMicroorganisms · 2025Article
- New Methodologies as Opportunities in the Study of Bacterial Biofilms, Including Food-Related Applications.Microorganisms · 2025Review
- Investigating enterohemorrhagicOpen veterinary journal · 2025Article
- Shiga toxin-producing Escherichia coli O157:H7 outbreak associated with school field trips at a farm animal exhibit-Tennessee, September-October 2023.Zoonoses and public health · 2024Article
- Impact of Selenium Nanoparticle-Enriched Lactobacilli Feeding Against Escherichia coli O157:H7 Infection of BALB/c Mice.Probiotics and antimicrobial proteins · 2024Article
- Further Evaluation of EnterohemorrhagicVaccines · 2024Article
- An Emerging Foodborne Pathogen Spotlight: A Bibliometric Analysis and Scholarly Review ofAntibiotics (Basel, Switzerland) · 2024Review
- Prevalence of Salmonella spp. and Escherichia coli in the feces of free-roaming wildlife throughout South Korea.PloS one · 2024Article
- A review of the mechanisms that confer antibiotic resistance in pathotypes ofFrontiers in cellular and infection microbiology · 2024Review
- Comparative Transcriptome Analysis of Shiga Toxin-ProducingMicroorganisms · 2023Article
- Occurrence and antimicrobial susceptibility patterns of Escherichia coli and Escherichia coli O157 isolated from cow milk and milk products, Ethiopia.Scientific reports · 2023Article
- Isolation, Characterization, and Comparative Genomic Analysis of Bacteriophage Ec_MI-02 from Pigeon Feces InfectingInternational journal of molecular sciences · 2023Article
- Detection of Escherichia coli O157:H7 in imported meat products from Saudi Arabian ports in 2017.Scientific reports · 2023Article
- Ophthalmic implications of biological threat agents according to the chemical, biological, radiological, nuclear, and explosives framework.Frontiers in medicine · 2023Review
- Complete genome analysis ofFrontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli O157:H7 is a notorious pathogen often contracted by intake of contaminated water or food. Infection with this agent is associated with a broad spectrum of illness ranging from mild diarrhea and hemorrhagic colitis to the potentially fatal hemolytic uremic syndrome (HUS). Treating E. coli O157:H7 infection with antimicrobial agents is associated with an increased risk of severe sequelae such as HUS. The difficulty in treating this bacterium using conventional modalities of antimicrobial agent administration has sparked an interest in investigating new therapeutic approaches to this bacterium. These approaches have included the use of probiotic agents and natural products with variable success rates. In addition, novel modalities and regimen of antimicrobial agent administration have been assessed in an attempt at decreasing their association with aggravating infection outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.